Merck & Co., Inc. 

MRK Price

What is Merck & Co. (MRK) stock on DropsTab?

Merck & Co., Inc. is a US multinational pharmaceutical company headquartered in Rahway, New Jersey, and one of the world's largest biopharmaceutical companies by revenue. On the crypto side, MRK exists only as a TradFi derivative: USDT-margined perpetual futures that track the NYSE-listed common stock around the clock. DropsTab classifies the asset under TradFi. The company generated $65.0 billion in worldwide sales in FY2025, led by the Keytruda oncology franchise.

Is there a Merck crypto token or MRK tokenized stock?

No. Merck & Co. has no native crypto token, no on-chain contract, and no tokenized-stock wrapper among the markets DropsTab tracks. Crypto exposure to Merck & Co. comes exclusively through USDT-settled perpetual futures contracts that mirror the NYSE share price. These contracts confer no share ownership and no shareholder rights. Any tokenized MRK products on other platforms are separately issued wrapper instruments, distinct from the venue-native perpetuals listed here.

Can you trade Merck stock on Binance or OKX?

Yes, through perpetual futures rather than spot. Per DropsTab data, MRK perpetuals trade as MRKUSDT on Binance Futures and as MRK-USDT-SWAP on OKX Futures, with additional contracts on Bitunix Futures and Gate.io Futures. No spot MRK markets and no DEX pairs exist, because there is no native token to list. Binance added MRKUSDT to its TradFi stock-perpetual line on August 28, 2026.

How do MRK perpetual futures track the NYSE share price?

MRK perpetual contracts track the underlying NYSE-listed stock through a funding-rate mechanism that anchors the futures price to the equity price. The contracts settle in USDT and trade continuously, unlike NYSE regular sessions. Exposure is purely synthetic: a long MRKUSDT position captures price movement but not share ownership, proxy voting rights, or direct dividend payments. Liquidity depends on derivatives order books on each venue rather than a spot market.

Do MRK perpetual futures pay Merck's dividend?

No. Perpetual futures holders receive no dividend, because the contracts confer no share ownership. The cash dividend belongs to holders of the underlying common stock: Merck & Co. pays a quarterly dividend raised to $0.85 per share for 2026, up from $0.81. The most recent ex-dividend date was September 15, 2026. Perpetual venues may reflect upcoming dividend dates through funding-rate adjustments instead of direct payouts.

What is the biggest revenue risk for Merck & Co.?

Keytruda concentration is the main revenue risk. Keytruda generated $31.7 billion in FY2025 — roughly half of Merck & Co.'s total $65.0 billion in worldwide sales — and US loss of exclusivity is expected in 2028. The company's counterweights are pipeline extensions such as subcutaneous Keytruda Qlex, approved in the US in September 2025, and Winrevair in pulmonary arterial hypertension. Revenue concentration of this scale makes the equity price highly sensitive to Keytruda developments.

Is Merck & Co. the same company as Merck KGaA?

No. Merck & Co. (NYSE: MRK) and Germany's Merck KGaA (Xetra: MRK) have been separate companies since 1917, when the US business became independent after expropriation under the Trading with the Enemy Act of 1917. George F. Merck repurchased the US operations at auction in 1919 for $3.5 million. Outside the US and Canada, Merck & Co. operates as Merck Sharp & Dohme (MSD). This page tracks the US Merck & Co.